List

<p>Eli Lilly’s newly approved monoclonal antibody, donanemab, offers a strategic shift in Alzheimer’s treatment — targeting established amyloid plaques, enabling early intervention, and introducing the possibility of treatment discontinuation.</p>

Alzheimer disease is standing on a paper, silhouette of a head with a damaged brain, dementia diagnosis, Parkinson´s awareness day

Kisunla: A Targeted, Timed Approach to Early Alzheimer’s Disease

Evolve Health

Evolve Health is a contributor-driven research publishing platform designed for healthcare professionals, researchers, and academics to share original, evidence-based articles, medical device reviews, and forward-thinking insights.

Articles are free to read for anyone, supporting open-access to credible healthcare content.

Contributors pay a publishing fee to submit their work, gaining visibility, authority, and permanent SEO-friendly hosting on a curated professional platform.

Readers must subscribe to participate in discussions, Q&As, and community threads—creating a paid, high-quality space for professional-level dialogue without trolls, spam, or noise.

Evolve Health’s core mission is to unify fragmented healthcare discourse and empower future healthcare leaders through open, intelligent, and evidence-backed communication.

